Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors Amira Pharmaceuticals, Inc. Announced that the U today.K sildenafil 100mg . Intellectual Property Office has granted patent number GB2461629, titled, ‘HETEROALKYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS,’ which includes coverage of Amira’s AM461 DP2 receptor antagonist. This is actually the second patent granted of a big estate filed by Amira Pharmaceuticals that describe novel small molecule inhibitors of the DP2 receptor. ‘This UK patent for AM461 is normally another significant milestone for the Amira DP2 program and clearly implies that Amira can efficiently develop patent-protected, novel medication candidates,’ said John Hutchinson, Ph.D., Vice President of Chemistry.

viagra for women

Amgen therapeutics have transformed the practice of medicine, helping millions of people all over the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a wide and deep pipeline of potential new medicines, Amgen remains focused on advancing science to dramatically improve people s lives.. Amgen’s Full Year 2011 Income Increased 4 Percent to $15.6 Billion Amgen reported total revenue increased 3 % during the fourth quarter of 2011 to $3,973 million versus $3,841 million in the fourth one fourth of 2010.